CONTENTS

SHORT COMMUNICATIONS

1. Opioid Analgesia in P450 Gene Cluster Knockout Mice: A Search for Analgesia-Relevant Isoforms. Lindsay B. Hough, Julia W. Nalwalk, Xinxin Ding, and Nico Scheer ........................................... 1326


3. Expression of Bama Minipig and Human CYP3A Enzymes: Comparison of the Catalytic Characteristics with Each Other and Their Liver Microsomes. Yicong Bian, Qingqing Yao, Haitao Shang, Jinxia Lei, HaiHong Hu, Kenan Guo, Huidi Jiang, Lushan Yu, Hong Wei, and Su Zeng ........................................... 1336


ARTICLES

5. Further Characterization of the Metabolism of Desloratadine and Its Cytochrome P450 and UDP-glucuronosyltransferase Inhibition Potential: Identification of Desloratadine as a Relatively Selective UGT2B10 Inhibitor. Faraz Kazmi, Phyllis Yerino, Joanna E. Barbara, and Andrew Parkinson ........................................... 1294


7. Determination of a Degradation Constant for CYP3A4 by Direct Suppression of mRNA in a Novel Human Hepatocyte Model, HepatoPac. Diane Ramsden, Jin Zhou, and Donald J. Tweedie ........................................... 1307

8. SUMOylation and Ubiquitylation Circuitry Controls Pregnane X Receptor Biology in Hepatocytes. Wengi Cui, Mengxi Sun, Nadezhda Galeva, Todd D. Williams, Yoshiaki Azuma, and Jeff L. Staudinger ........................................... 1316

9. Damage to the Brain Serotonergic System Increases the Expression of Liver Cytochrome P450. Marta Rysz, Ewa Bromek, Anna Haduch, Anna Sadkierska-Chudy, and Wladyslaw A. Daniel ........................................... 1345


11. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft. Thomas J. Raub, Graham N. Wishart, Palaniappan Kulanthaivel, Brian A. Staton, Rose T. Ajamie, Geri A. Sawada, Lawrence M. Gelbert, Harlan E. Shannon, Concepcion Sanchez-Martinez, and Alfonso De Dios ........................................... 1360


Continued on next page
Cross-Species Differences in the Preclinical Pharmacokinetics of CT7758, an α4β1/α4β7 Integri
Antagonist, Hugues Chanteux, Ludovicus Staelens, Valérie Mancel, Brigitte Gerin, David Boucaut, Chandra Prakash, and Jean-Marie Nicolas ............................ 1381

Influence of ABCB1 Genotype in Collies on the Pharmacokinetics and Pharmacodynamics of Loperamide in a Dose-Escalation Study, Michael J. Myers, Marilyn Martinez, Hui Li, Junshan Qiu, Lisa Troutman, Michele Sharkey, and Haile F. Yancy .............................. 1392

Supplemental material is available online at http://dmd.aspetjournals.org.

About the cover: Figure 1. (A) General structure of non-cleavable antibody maytansiod conjugate (B) Mechanism of ADC activity where, (A) localization of ADC to the tumor cell, (B) binding of ADC to specific antigen, (C) internalization into the endosome release the antigen from ADC, (D) catabolism of ADC in the lysosome, (E) release of Lys-MCC-DM1 into the cytoplasm, and (F) binding of Lys-MCC-DM1to tubulin resulting in cell cycle arrest and apoptosis. Please see the article by Rock et al. (dx.doi.org/10.1124/dmd.115.064253).